Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Hansson

Showing results (101-110 of 199) with videos related to

Pageof 20
Sort By:
Acta Oncologica (Stockholm, Sweden)|April 30, 2013
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanomaYvonne Brandberg, Hemming Johansson, Steinar Aamdal, et al.
Critical Reviews in Oncology/Hematology|August 10, 2012
Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert reviewPaolo A Ascierto, Helen J Gogas, Jean Jacques Grob, et al.
The Lancet. Oncology|January 25, 2011
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trialJohan Hansson, Steinar Aamdal, Lars Bastholt, et al.
Scandinavian Journal of Urology and Nephrology|May 15, 2003
Bladder neoplasms--regions at chromosome 9 with putative tumour suppressor genesTakashi Wada, Petra Berggren, Gunnar Steineck, et al.
American Journal of Audiology|December 10, 2015
Internet-Based Acceptance and Commitment Therapy for Psychological Distress Experienced by People With Hearing Problems: Study Protocol for a Randomized Controlled TrialPeter Molander, Hugo Hesser, Sandra Weineland, et al.
Cell Death & Disease|September 12, 2019
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation statusIshani Das, Margareta Wilhelm, Veronica Höiom, et al.
Cancer Immunology, Immunotherapy : CII|July 5, 2014
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanomaIsabel Poschke, Tanja Lövgren, Lars Adamson, et al.
Cancer Immunology Research|April 30, 2014
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 productionYago Pico de Coaña, Isabel Poschke, Giusy Gentilcore, et al.
The Journal of Investigative Dermatology|September 18, 2009
Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterationsBraslav Jovanovic, Suzanne Egyhazi, Malihe Eskandarpour, et al.
Melanoma Research|August 8, 2013
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell linesCarolina Hertzman Johansson, Alireza Azimi, Marianne Frostvik Stolt, et al.
Pageof 20

Showing results (101-110 of 199) with videos related to

Sort By:
Pageof 20
Acta Oncologica (Stockholm, Sweden)|April 30, 2013
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanomaYvonne Brandberg, Hemming Johansson, Steinar Aamdal, et al.
Critical Reviews in Oncology/Hematology|August 10, 2012
Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert reviewPaolo A Ascierto, Helen J Gogas, Jean Jacques Grob, et al.
The Lancet. Oncology|January 25, 2011
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trialJohan Hansson, Steinar Aamdal, Lars Bastholt, et al.
Scandinavian Journal of Urology and Nephrology|May 15, 2003
Bladder neoplasms--regions at chromosome 9 with putative tumour suppressor genesTakashi Wada, Petra Berggren, Gunnar Steineck, et al.
American Journal of Audiology|December 10, 2015
Internet-Based Acceptance and Commitment Therapy for Psychological Distress Experienced by People With Hearing Problems: Study Protocol for a Randomized Controlled TrialPeter Molander, Hugo Hesser, Sandra Weineland, et al.
Cell Death & Disease|September 12, 2019
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation statusIshani Das, Margareta Wilhelm, Veronica Höiom, et al.
Cancer Immunology, Immunotherapy : CII|July 5, 2014
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanomaIsabel Poschke, Tanja Lövgren, Lars Adamson, et al.
Cancer Immunology Research|April 30, 2014
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 productionYago Pico de Coaña, Isabel Poschke, Giusy Gentilcore, et al.
The Journal of Investigative Dermatology|September 18, 2009
Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterationsBraslav Jovanovic, Suzanne Egyhazi, Malihe Eskandarpour, et al.
Melanoma Research|August 8, 2013
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell linesCarolina Hertzman Johansson, Alireza Azimi, Marianne Frostvik Stolt, et al.
Pageof 20